NRC Health Q2 revenue rises on the back of product innovation

NRC Health

28/07/2026 21:10

Overview
Healthcare experience solutions firm's Q2 revenue rose 4% yr/yr to $35.4 mln
Adjusted EPS for Q2 was $0.31, with GAAP net loss reflecting stock and bonus costs
Total recurring contract value grew 11% yr/yr to $151.9 mln

Outlook
Company expects strong second half 2026 based on recent bookings performance
NRC Health sees rising demand for healthcare experience improvement and governance solutions

Result Drivers
TRCV GROWTH - Double-digit increase in total recurring contract value, which management views as a leading indicator for future revenue
SALES AND DELIVERY EXECUTION - CEO cited strong go-to-market and solutions delivery execution as contributing to Q2 performance
PRODUCT INNOVATION - Ongoing commercialization of product innovations contributed to quarterly performance, according to CEO

Company press release: ID:nBw2r2b3Da

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$35.39 mln
$34.90 mln (1 Analyst)
Q2 Adjusted EPS
Beat
$0.31
$0.14 (1 Analyst)
Q2 Net Loss
 
$3.28 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the advertising & marketing peer group is "buy"
Wall Street's median 12-month price target for NRC Health is $23.00, about 8.1% above its July 27 closing price of $21.27

Reuters Recommended Reads
July 28 - IQVIA raises annual profit forecast on clinical research demand
July 28 - Philips falls 9% as weak orders, China concerns overshadow outlook hike
July 28 - Centene flags weakening Medicaid membership, shares fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)